Literature DB >> 18338841

Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections.

Steven J Brickner1, Michael R Barbachyn, Douglas K Hutchinson, Peter R Manninen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18338841     DOI： 10.1021/jm800038g

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  40 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

Review 2.  Resistance to linezolid caused by modifications at its binding site on the ribosome.

Authors:  Katherine S Long; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

3.  Motualevic acids and analogs: synthesis and antimicrobial structure-activity relationships.

Authors:  Pradeep Cheruku; Jessica L Keffer; Cajetan Dogo-Isonagie; Carole A Bewley
Journal:  Bioorg Med Chem Lett       Date:  2010-06-09       Impact factor: 2.823

4.  Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis.

Authors:  Rebecca A Keel; Andre Schaeftlein; Charlotte Kloft; J Samuel Pope; R Frederic Knauft; Marianne Muhlebach; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

5.  Antibacterial properties and mode of action of a short acyl-lysyl oligomer.

Authors:  Fadia Zaknoon; Hadar Sarig; Shahar Rotem; Liran Livne; Andrey Ivankin; David Gidalevitz; Amram Mor
Journal:  Antimicrob Agents Chemother       Date:  2009-06-01       Impact factor: 5.191

6.  The genetic environment of the cfr gene and the presence of other mechanisms account for the very high linezolid resistance of Staphylococcus epidermidis isolate 426-3147L.

Authors:  Jacqueline LaMarre; Rodrigo E Mendes; Teresa Szal; Stefan Schwarz; Ronald N Jones; Alexander S Mankin
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

Review 7.  Fragment-based inhibitor discovery against β-lactamase.

Authors:  Derek A Nichols; Adam R Renslo; Yu Chen
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

8.  Total syntheses and initial evaluation of [Ψ[C(═S)NH]Tpg⁴]vancomycin, [Ψ[C(═NH)NH]Tpg⁴]vancomycin, [Ψ[CH₂NH]Tpg⁴]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptide antibiotics.

Authors:  Akinori Okano; Atsushi Nakayama; Kejia Wu; Erick A Lindsey; Alex W Schammel; Yiqing Feng; Karen C Collins; Dale L Boger
Journal:  J Am Chem Soc       Date:  2015-03-09       Impact factor: 15.419

9.  In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Authors:  S Flanagan; K Bartizal; S L Minassian; E Fang; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

Review 10.  [Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].

Authors:  Sandra Rincón; Diana Panesso; Lorena Díaz; Lina P Carvajal; Jinnethe Reyes; José M Munita; César A Arias
Journal:  Biomedica       Date:  2014-04       Impact factor: 0.935
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.